{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-015212","form_type":"8-K","ticker":"ONCO","cik":"0001782107","company_name":"Onconetix, Inc.","filed_at":"2026-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.157781+00:00","generated_at":"2026-05-16T03:05:31.429940+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Onconetix to acquire Realbotix in reverse merger; Realbotix holders to own 75-90%","bullets":["Onconetix issues shares to Realbotix seller such that seller owns 75%–90% of fully diluted shares based on Net Cash at closing.","Closing requires Onconetix to have at least $12.5M Net Cash and enter a $125M equity line of credit.","Post-closing board: 5 directors with 4 designated by Realbotix and 1 by Onconetix.","Realbotix is an AI humanoid robotics company with U.S. manufacturing, proprietary AI, and multilingual robots.","Termination fee: $500k plus expenses (capped at $500k); additional $1.5M if Buyer Superior Proposal closes."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-015212","json":"https://secwatch.observer/filing/0001213900-26-015212.json","markdown":"https://secwatch.observer/filing/0001213900-26-015212.md","text":"https://secwatch.observer/filing/0001213900-26-015212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026015212/0001213900-26-015212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026015212/ea0276704-8k425_onconet.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:05:31.429940+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6f9f060c6115e4ce05589769e2f3db0344b5176","claim":"Onconetix, Inc. entered into Share Exchange Agreement with Realbotix Corp., Simulacra Corporation, and Realbotix, LLC (effective 2026-02-11).","evidence_excerpt":"On February 11, 2026, Onconetix, Inc, a Delaware corporation (“ Onconetix ” or “ Buyer ”), entered into a Share Exchange Agreement (the “ Share Exchange Agreement ”), by and among (i) Onconetix, (ii) Realbotix Corp., a company existing under the laws of the Province of Ontario (“ Parent ”), (iii) Simulacra Corporation, a Delaware corporation and a wholly-owned subsidiary of Parent (the “ Seller ”) and (iv) Realbotix, LLC, a Delaware limited liability company and wholly owned subsidiary of the Seller (the “ Company ” or “ Realbotix ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1782107/000121390026015212/0001213900-26-015212-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Realbotix Corp., Simulacra Corporation, and Realbotix, LLC"},{"label":"Effective","value":"2026-02-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}